Search

Your search keyword '"González-Mazón, Íñigo"' showing total 11 results
Start Over Author "González-Mazón, Íñigo"
11 results on '"González-Mazón, Íñigo"'

1. Systemic treatment in sarcoidosis: Experience over two decades

Author

Fernández-Ramón, Raúl, Gaitán-Valdizán, Jorge J., González-Mazón, Iñigo, Sánchez-Bilbao, Lara, Martín-Varillas, José L., Martínez-López, David, Demetrio-Pablo, Rosalía, González-Vela, M.Carmen, Ferraz-Amaro, Iván, Castañeda, Santos, González-Gay, Miguel A., and Blanco, Ricardo

Published
2023
Full Text
View/download PDF

2. Cardiovascular and disease-related features associated with extra-articular manifestations in axial spondyloarthritis. A multicenter study of 888 patients

Author

Rueda-Gotor, Javier, Ferraz-Amaro, Iván, Genre, Fernanda, González Mazón, Iñigo, Corrales, Alfonso, Portilla, Virginia, Llorca, Javier, Agudo-Bilbao, Mario, Aurrecoechea, Elena, Expósito, Rosa, Hernández-Hernández, Vanesa, Quevedo-Abeledo, Juan Carlos, Rodríguez-Lozano, Carlos, Lopez-Medina, Clementina, Ladehesa-Pineda, María Lourdes, Castañeda, Santos, Vicente, Esther F., Fernández-Carballido, Cristina, Martínez-Vidal, M Paz, Castro-Corredor, David, Anino-Fernández, Joaquín, Peiteado, Diana, Plasencia-Rodríguez, Chamaida, Vivar, María Luz García, Galíndez-Agirregoikoa, Eva, Perez, Esther Montes, Fernández Díaz, Carlos, Blanco, Ricardo, and González-Gay, Miguel Ángel

Published
2022
Full Text
View/download PDF

3. Factors associated with atherosclerosis in radiographic and non-radiographic axial spondyloarthritis. A multicenter study on 838 patients

Author

Rueda-Gotor, Javier, Ferraz-Amaro, Iván, Genre, Fernanda, González-Mazón, Iñigo, Corrales, Alfonso, Calvo-Rio, Vanesa, Portilla, Virginia, Llorca, Javier, Expósito, Rosa, Hernández-Hernández, Vanesa, Quevedo-Abeledo, Juan Carlos, Rodríguez-Lozano, Carlos, Lopez-Medina, Clementina, Ladehesa-Pineda, María Lourdes, Castañeda, Santos, Vicente, Esther F., Fernández-Carballido, Cristina, Martínez-Vidal, M Paz, Castro-Corredor, David, Anino-Fernández, Joaquín, Peiteado, Diana, Plasencia-Rodríguez, Chamaida, García-Vivar, María Luz, Galíndez-Agirregoikoa, Eva, Montes-Perez, Esther, Fernández-Díaz, Carlos, Blanco, Ricardo, and González-Gay, Miguel Ángel

Published
2022
Full Text
View/download PDF

4. Subclinical atherosclerotic disease in ankylosing spondylitis and non-radiographic axial spondyloarthritis. A multicenter study on 806 patients

Author

González Mazón, Iñigo, Rueda-Gotor, Javier, Ferraz-Amaro, Iván, Genre, Fernanda, Corrales, Alfonso, Calvo Rio, Vanesa, Palmou Fontana, Natalia, Portilla, Virginia, Llorca, Javier, Mata, Cristina, Hernández-Hernández, Vanesa, Quevedo-Abeledo, Juan Carlos, Rodríguez-Lozano, Carlos, Lopez Medina, Clementina, Ladehesa-Pineda, María Lourdes, Castañeda, Santos, Vicente, Esther F., Fernández-Carballido, Cristina, Martínez-Vidal, María Paz, Castro-Corredor, David, Anino-Fernández, Joaquín, Peiteado, Diana, Plasencia-Rodríguez, Chamaida, García-Vivar, María Luz, Galíndez-Agirregoikoa, Eva, Montes Perez, Esther, Fernández Díaz, Carlos, Blanco, Ricardo, and González-Gay, Miguel Angel

Published
2021
Full Text
View/download PDF

5. Vaspin in atherosclerotic disease and cardiovascular risk in axial spondyloarthritis: a genetic and serological study

Author

Rueda-Gotor, Javier, López-Mejías, Raquel, Remuzgo-Martínez, Sara, Pulito-Cueto, Verónica, Corrales, Alfonso, Lera-Gómez, Leticia, Portilla, Virginia, González-Mazón, Íñigo, Blanco, Ricardo, Expósito, Rosa, Mata, Cristina, Llorca, Javier, Hernández-Hernández, Vanesa, Rodríguez-Lozano, Carlos, Barbarroja, Nuria, Castro, Rafaela Ortega, Vicente, Esther, Fernández-Carballido, Cristina, Martínez-Vidal, María Paz, Castro-Corredor, David, Anino-Fernández, Joaquín, Peiteado, Diana, Plasencia-Rodríguez, Chamaida, Galíndez-Agirregoikoa, Eva, García-Vivar, María Luz, Gualillo, Oreste, Quevedo-Abeledo, Juan Carlos, Castañeda, Santos, Ferraz-Amaro, Iván, González-Gay, Miguel Á., and Genre, Fernanda

Published
2021
Full Text
View/download PDF

6. Irisin as a Novel Biomarker of Subclinical Atherosclerosis, Cardiovascular Risk and Severe Disease in Axial Spondyloarthritis

Author

Remuzgo-Martínez, Sara, primary, Rueda-Gotor, Javier, additional, Pulito-Cueto, Verónica, additional, López-Mejías, Raquel, additional, Corrales, Alfonso, additional, Lera-Gómez, Leticia, additional, Pérez-Fernández, Raquel, additional, Portilla, Virginia, additional, González-Mazón, Íñigo, additional, Blanco, Ricardo, additional, Expósito, Rosa, additional, Mata, Cristina, additional, Llorca, Javier, additional, Hernández-Hernández, Vanesa, additional, Rodríguez-Lozano, Carlos, additional, Barbarroja, Nuria, additional, Ortega-Castro, Rafaela, additional, Vicente, Esther, additional, Fernández-Carballido, Cristina, additional, Martínez-Vidal, María Paz, additional, Castro-Corredor, David, additional, Anino-Fernández, Joaquín, additional, Peiteado, Diana, additional, Plasencia-Rodríguez, Chamaida, additional, Galíndez-Agirregoikoa, Eva, additional, García-Vivar, María Luz, additional, Vegas-Revenga, Nuria, additional, Urionaguena, Irati, additional, Gualillo, Oreste, additional, Quevedo-Abeledo, Juan Carlos, additional, Castañeda, Santos, additional, Ferraz-Amaro, Iván, additional, González-Gay, Miguel Á., additional, and Genre, Fernanda, additional

Published
2022
Full Text
View/download PDF

7. Additional file 1 of Vaspin in atherosclerotic disease and cardiovascular risk in axial spondyloarthritis: a genetic and serological study

Author

Rueda-Gotor, Javier, López-Mejías, Raquel, Remuzgo-Martínez, Sara, Pulito-Cueto, Verónica, Corrales, Alfonso, Lera-Gómez, Leticia, Portilla, Virginia, González-Mazón, Íñigo, Blanco, Ricardo, Expósito, Rosa, Mata, Cristina, Llorca, Javier, Hernández-Hernández, Vanesa, Rodríguez-Lozano, Carlos, Barbarroja, Nuria, Castro, Rafaela Ortega, Vicente, Esther, Fernández-Carballido, Cristina, Martínez-Vidal, María Paz, Castro-Corredor, David, Anino-Fernández, Joaquín, Peiteado, Diana, Chamaida Plasencia-Rodríguez, Galíndez-Agirregoikoa, Eva, García-Vivar, María Luz, Gualillo, Oreste, Quevedo-Abeledo, Juan Carlos, Castañeda, Santos, Ferraz-Amaro, Iván, González-Gay, Miguel Á., and Genre, Fernanda

Abstract

Additional file 1: Supplementary Table 1. Demographic, clinical, laboratory, and cardiovascular disease-related characteristics in patients with axial spondyloarthritis carrying or not the A allele of vaspin rs7159023.

Published
2021
Full Text
View/download PDF

8. Anti-IL-6 Receptor Tocilizumab in Refractory Graves’ Orbitopathy: National Multicenter Observational Study of 48 Patients

Author

Sánchez-Bilbao, Lara, primary, Martínez-López, David, additional, Revenga, Marcelino, additional, López-Vázquez, Ángel, additional, Valls-Pascual, Elia, additional, Atienza-Mateo, Belén, additional, Valls-Espinosa, Beatriz, additional, Maiz-Alonso, Olga, additional, Blanco, Ana, additional, Torre-Salaberri, Ignacio, additional, Rodríguez-Méndez, Verónica, additional, García-Aparicio, Ángel, additional, Veroz-González, Raúl, additional, Jovaní, Vega, additional, Peiteado, Diana, additional, Sánchez-Orgaz, Margarita, additional, Tomero, Eva, additional, Toyos-Sáenz de Miera, Francisco J., additional, Pinillos, Valvanera, additional, Aurrecoechea, Elena, additional, Mora, Ángel, additional, Conesa, Arantxa, additional, Fernández-Prada, Manuel, additional, Troyano, Juan A., additional, Calvo-Río, Vanesa, additional, Demetrio-Pablo, Rosalía, additional, González-Mazón, Íñigo, additional, Hernández, José L., additional, Castañeda, Santos, additional, González-Gay, Miguel Á., additional, and Blanco, Ricardo, additional

Published
2020
Full Text
View/download PDF

9. Diseño e ingeniería de proteínas en biomedicina : posibles agonistas y antagonistas de la hepcidina

Author

González Mazón, Íñigo, Moncalián Montes, Gabriel, Universidad de Cantabria, and Moncalián, Gabriel

Subjects
Metabolismo, Hepcidina, Hepcidin, Iron metabolism, Biomedicina, Hierro
Abstract

[ES]: Los trastornos en el metabolismo del hierro pueden causar enfermedades tanto por defecto como por exceso del mismo en el organismo, no existiendo una cura actualmente para ninguno de ellos. Recientemente se ha descrito una proteína, la hepcidina, que es la encargada de regular la homeostasis de este metal, lo que abre todo un abanico de posibles terapias dirigidas contra esta diana. En este trabajo se hace un resumen de los nuevos fármacos que se han ido diseñando (aún no hay ninguno comercializado) y se proponen nuevas opciones terapéuticas utilizando la ingeniería de proteínas como herramienta para crear agonistas y antagonistas de la hepcidina., [EN]: The iron metabolism disorders can cause both iron overload and iron deficiency diseases, for which there is no cure at this moment. Recently a new protein, hepcidin, has been described, and its function is to regulate the homeostasis of this metal, which opens a new bunch of possible therapies against this target. In this work there is a summary of the new drugs which have been designed (none of them is comercialized yet) and new therapeuitcal options are proposed using the protein engineering as a tool to create both agonists and antagonists of the hepcidin.

Published
2016

10. Diseño e ingeniería de proteínas en biomedicina : posibles agonistas y antagonistas de la hepcidina

Author

Moncalián, Gabriel, González Mazón, Íñigo, Moncalián, Gabriel, and González Mazón, Íñigo

Abstract

[ES]: Los trastornos en el metabolismo del hierro pueden causar enfermedades tanto por defecto como por exceso del mismo en el organismo, no existiendo una cura actualmente para ninguno de ellos. Recientemente se ha descrito una proteína, la hepcidina, que es la encargada de regular la homeostasis de este metal, lo que abre todo un abanico de posibles terapias dirigidas contra esta diana. En este trabajo se hace un resumen de los nuevos fármacos que se han ido diseñando (aún no hay ninguno comercializado) y se proponen nuevas opciones terapéuticas utilizando la ingeniería de proteínas como herramienta para crear agonistas y antagonistas de la hepcidina., [EN]: The iron metabolism disorders can cause both iron overload and iron deficiency diseases, for which there is no cure at this moment. Recently a new protein, hepcidin, has been described, and its function is to regulate the homeostasis of this metal, which opens a new bunch of possible therapies against this target. In this work there is a summary of the new drugs which have been designed (none of them is comercialized yet) and new therapeuitcal options are proposed using the protein engineering as a tool to create both agonists and antagonists of the hepcidin.

Published
2016

11. Biologic therapy in refractory neurobehçet's disease: a multicentre study of 41 patients and literature review.

Author

Herrero-Morant A, Martín-Varillas JL, Castañeda S, Maíz O, Sánchez J, Ortego N, Raya E, Prior-Español Á, Moriano C, Melero-González RB, Graña-Gil J, Urruticoechea-Arana A, Ramos-Calvo Á, Loredo-Martínez M, Salgado-Pérez E, Sivera F, Torre I, Narváez J, Andreu JL, Martínez-González O, Torre RG, Fernández-Aguado S, Romero-Yuste S, González-Mazón Í, Álvarez-Reguera C, Hernández JL, González-Gay MÁ, and Blanco R

Subjects
Humans, Female, Adult, Infliximab therapeutic use, Adalimumab therapeutic use, Etanercept therapeutic use, Glucocorticoids, Treatment Outcome, Multicenter Studies as Topic, Immunosuppressive Agents therapeutic use, Biological Therapy
Abstract

Objectives: To assess efficacy and safety of biologic therapy (BT) in neurobehçet's disease (NBD) refractory to glucocorticoids and at least one conventional immunosuppressive drug., Methods: Open-label, national, multicentre study. NBD diagnosis was based on the International Consensus Recommendation criteria. Outcome variables were efficacy and safety. Main efficacy outcome was clinical remission. Other outcome variables analysed were glucocorticoid-sparing effect and improvement in laboratory parameters., Results: We studied 41 patients [21 women; age 40.6 (10.8) years]. Neurological damage was parenchymal (n = 33, 80.5%) and non-parenchymal (n = 17, 41.5%). First BTs used were infliximab (n = 19), adalimumab (n = 14), golimumab (n = 3), tocilizumab (n = 3) and etanercept (n = 2). After 6 months of BT, neurological remission was complete (n = 23, 56.1%), partial (n = 15, 37.6%) and no response (n = 3, 7.3%). In addition, median (IQR) dose of oral prednisone decreased from 60 (30-60) mg/day at the initial visit to 5 (3.8-10) mg/day after 6 months (P < 0.001). It was also the case for mean erythrocyte sedimentation rate [31.5 (25.6)-15.3 (11.9) mm/1st h, P = 0.011] and median (IQR) C-reactive protein [1.4 (0.2-12.8) to 0.3 (0.1-3) mg/dl, P = 0.001]. After a mean follow-up of 57.5 months, partial or complete neurological remission persisted in 37 patients (90.2%). BT was switched in 22 cases (53.6%) due to inefficacy (n = 16) or adverse events (AEs) (n = 6) and discontinued due to complete prolonged remission (n = 3) or severe AE (n = 1). Serious AEs were observed in two patients under infliximab treatment., Conclusions: BT appears to be effective and relatively safe in refractory NBD., (© The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results